Posted by Carl W. Dieffenbach, Ph.D., Anthony S. Fauci, M.D. on March 8, 2013 at 2:43 PM
As part of the National HIV/AIDS Strategy, as we move forward with our research agenda we must engage in serious discussions on the criteria, risks and ethics involved in all our studies, including the idea of stopping antiretroviral therapy in individuals who may be “cured.
Posted by Ronald Valdiserri on March 6, 2013 at 10:45 AM
Ronald Valdiserri and Grant Colfax discuss the role science plays in helping us achieve the vision of the National HIV/AIDS Strategy as well as some of the important findings being announced at 2013 Conference on Retroviruses and Opportunistic Infections.
Posted by Robynn Sturm Steffen on March 1, 2013 at 2:15 PM
On Wednesday, ViiV Healthcare announced it would grant a voluntary license to enable low-cost supply of a key pediatric HIV medicine in the 118 countries in which 98.7% of all HIV-positive children reside. Voluntary licenses like this one play an important role in making affordable HIV medicines available in developing countries and stimulating innovation for those markets.
On November 30th at 3:00 p.m. ET join us for a special session of White House Office Hours with Senior Advisor Valerie Jarrett and Gayle Smith, Senior Director, National Security Council in honor of World AIDS Day 2012.